Observational studyBMC cardiovascular disorders2026
Impact of SGLT2 ınhibitors on nutritional and ımmunologic status in chronic heart failure.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic nutritional index (PNI), combining serum albumin and lymphocyte count, is a validated marker of nutritional-inflammatory status and an independent predictor of outcomes in heart failure (HF). Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) improve cardiovascular and renal prognosis; however, their effect on dynamic changes in PNI remains insufficiently defined.
methodsThis study included 365 patients with chronic HF receiving stable guideline-directed medical therapy. Patients treated with SGLT2 inhibitors in addition to triple therapy constituted the treatment group (n = 209), while those without SGLT2 inhibitor therapy formed the control group (n = 156). PNI was calculated at baseline and at 12-month follow-up. The primary endpoint was the change in PNI (ΔPNI). Linear regression analyses were performed to determine independent predictors of ΔPNI.
resultsBaseline PNI did not differ significantly between the treatment and control groups (50.15 ± 8.52 vs. 50.12 ± 8.05, p = 0.196 At 12 months, PNI increased significantly in the SGLT2 inhibitor group and declined in the control group, yielding higher follow-up PNI with SGLT2 inhibitor therapy (52.48 ± 8.50 vs. 46.07 ± 9.35, p < 0.001). HF-related rehospitalizations were more frequent in the control group (p < 0.001). In multivariate regression, SGLT2 inhibitor use was independently associated with higher ΔPNI (B = 5.468, p < 0.001), whereas the other parameters were not independently associated with higher or lower ΔPNI. Furthermore, in ejection fraction (EF)-stratified longitudinal analysis, the increase in PNI was most pronounced in patients with heart failure with mildly reduced EF (HFmrEF) and heart failure with preserved EF (HFpEF) (ΔPNI + 4.63 and + 3.16, respectively; both Bonferroni-adjusted p < 0.0167), whereas the change in heart failure with reduced EF (HFrEF) (+ 1.33) did not remain significant after adjustment.
conclusionsSGLT2 inhibitor therapy was associated with significant longitudinal improvement in PNI, particularly in patients with HFmrEF and HFpEF, whereas the change in HFrEF did not reach the Bonferroni-adjusted level of significance. These findings suggest that SGLT2 inhibitors may favorably modify the nutritional-inflammatory profile, with more pronounced effects observed in patients with preserved or mildly reduced ejection fraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.